Date of Award

January 2018

Document Type

Thesis

Degree Name

Medical Doctor (MD)

Department

Medicine

First Advisor

Oscar R. Colegio

Abstract

This study demonstrates how PDVC57 is an effective pre-clinical model to test immunomodulatory medications for cutaneous SCC in immunocompetent C57Bl/6 mice. We demonstrated the first analysis of myeloid populations within the cutaneous SCC tumor microenvironment and found increased Arg1 expression in TAMs. TAM-inhibition using topically delivered Nor-NOHA effectively decreased tumor size and represents a promising new modality to potentially treat cutaneous SCC. Further clinical trials are warranted to test nor-NOHA in patients with cutaneous SCC and to determine if monotherapy or combination with checkpoint inhibition is more effective.

Comments

This thesis is restricted to Yale network users only. It will be made publicly available on 06/25/2100

Share

COinS